Clinical Genomics to Present Data at ASCO Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer

BRIDGEWATER, N.J., May 31, 2017 -- Clinical Genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data demonstrating the utility of Colvera™, its 2-gene blood test, in measuring minimal residual disease in patients with invasive colorectal cancer (CRC) will be presented at the American Society of Clinical Oncology 2017 Annual Meeting in Chicago, IL from June 2 – 6.

Selected study for presentation at the meeting include:

  • Circulating tumor DNA analysis before and after resection for colorectal cancer

    Presenter: Graeme Young, AM, MB BS MD FRACP FTSE AGAF
    Abstract Number: 3597
    Poster Board Number: 220

     

Data will be presented during Poster Session Title Gastrointestinal (Colorectal) Cancer, on Saturday, June 3 from 8:00 am – 11:30 am CT in Hall A.

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 50 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.

About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed and recently launched Colvera™, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects methylated DNA from two genes, BCAT1 and IKZF1.

Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

For more information, please visit www.clinicalgenomics.com and www.colveratest.com.

 

###